MO
Morepen Laboratories Ltd (MOREPENLAB)
₹90.15
Mkt cap
₹4,940 Cr
P/E ratio
26.20
P/B
3.58
Div yield
0.22%
ROE
5.33%
ROCE
8.05%
EPS (TTM)
₹3.44
Book value
₹25
52W range
33–151
Sector
Healthcare
Price history
Previous close
Morepen Laboratories Ltd is engaged in the business of manufacturing, producing, developing and marketing a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations and also the Home Health products. [1]
NSE MOREPENLABBSE 500288
Health check
Constructive
ValuationCheap
ProfitabilityWeak
GrowthHigh
TechnicalsNeutral
52-week range
−40.18% from high₹90
₹33+172.77% from low₹151
Current
₹90.15
Prev close
₹90.77
Day
−0.68%
Price performance
1D
−0.79%
1W
−9.62%
1M
−23.47%
3M
−6.65%
6M
+109.52%
1Y
+94.62%
YTD
+114.49%
Financials
Revenue, profit & margin
P/E ratio
26.2×
MOREPENLAB is 19% below the sector median of 32.5×
MOREPENLAB26.2×
Sector median32.5×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 422 | 445 | 423 | 455 | 438 | 453 | 466 | 425 | 412 | 484 | 485 | 570 | 746 | |
| YoY Sales growth | +5% | +28% | +16% | +14% | +4% | +2% | +10% | -7% | -6% | +7% | +4% | +34% | +81% | |
| Expenses | 388 | 394 | 375 | 404 | 394 | 417 | 424 | 401 | 381 | 438 | 460 | 488 | 623 | |
| Operating Profit | 34 | 51 | 48 | 52 | 44 | 36 | 42 | 24 | 31 | 46 | 24 | 83 | 123 | |
| OPM % | 8% | 11% | 11% | 11% | 10% | 8% | 9% | 6% | 7% | 10% | 5% | 14% | 16% | |
| Other Income | 3 | 4 | 4 | 3 | 5 | 5 | 5 | 4 | 30 | 4 | 8 | 5 | 9 | |
| Interest | 0 | 2 | 1 | 1 | 1 | 1 | 5 | 4 | 4 | 4 | 4 | 5 | 5 | |
| Depreciation | 8 | 8 | 10 | 6 | 2 | 5 | 16 | 9 | 11 | 10 | 6 | 8 | 10 | |
| Profit before tax | 29 | 44 | 42 | 48 | 46 | 35 | 26 | 16 | 46 | 35 | 23 | 75 | 117 | |
| Tax % | 26% | 27% | 32% | 25% | 24% | 24% | 21% | 26% | 10% | 22% | 33% | 24% | 24% | |
| Net Profit | 21 | 32 | 29 | 36 | 35 | 27 | 20 | 11 | 41 | 28 | 16 | 56 | 89 | |
| EPS in Rs | 0.42 | 0.63 | 0.55 | 0.71 | 0.64 | 0.49 | 0.37 | 0.20 | 0.75 | 0.50 | 0.29 | 1.03 | 1.62 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202635.66%Promoter
Promoters35.66%
FIIs3.43%1.97
DIIs1.70%0.42
Public59.19%2.40
Government0.01%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,884.90 | 36.76 | 4,52,251 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,180.50 | 86.86 | 2,96,807 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,689.50 | 82.16 | 1,78,374 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,294.60 | 92.53 | 1,23,980 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,200.00 | 26.42 | 1,19,700 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,390.20 | 41.47 | 1,16,119 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,415.00 | 36.81 | 1,14,316 | 0.92% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Morepen Labs. | ₹90.15 | 26.20 | 4,940 | 0.22% | 89 | +400.33% | 747 | +81.37% | 8.05% |
| Median: 160 Co. | ₹432.20 | 32.47 | 1,983 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports15
Concall transcripts60
PPTOct 2026PPTAug 2026PPTMay 2026PPTFeb 2026PPTNov 2025PPTAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024PPTAug 2024RECAug 2024TranscriptMay 2024PPTMay 2024RECMay 2024PPTMay 2024TranscriptFeb 2024PPTFeb 2024TranscriptNov 2023PPTNov 2023
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 19 Nov - Investor call on 25 Nov 2026 to discuss Q2 FY27 financial performance.Announcement under Regulation 30 (LODR)-Credit Rating 14 Nov - INFOMERICS upgraded Morepen Laboratories' bank facilities rating to IVR A/Stable on 13 November 2026.Announcement under Regulation 30 (LODR)-Press Release / Media Release 9 Nov - Morepen launches Desloratadine Rx generics in the U.S. and files first ANDA for Sitagliptin.Announcement under Regulation 30 (LODR)-Change in Management 31 Oct - Nishant Jayesh Doshi resigns as Vice President, Corporate Finance & Investor Relations, effective 31 October 2026.Announcement under Regulation 30 (LODR)-Newspaper Publication 28 Oct - Newspaper Publication financial results for the quarter and half year ended 30 September 2026 and special window for transfer and dematerialization of physical shares






